Efficacy analysis of ultrashort wave therapy as adjunctive treatment for pediatric patients with macrolide-resistant Mycoplasma pneumoniae pneumonia
Abstract
Background The incidence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP) has been increasing in children, resulting in prolonged illness and complications. This study aimed to evaluate the effect of ultrashort-wave therapy (USWT) as a second-line therapy in patients with MRMPP. Methods This is a retrospective controlled practice clinical study of 112 children hospitalized with MRMPP, assigned to a control group (n = 75) who received standard therapy, or a USWT group (n = 37), who received standard therapy plus USWT. The groups were assigned based on parental preference, not randomization. The primary outcomes studied were length of stay, pulmonary lesion resolution, and new lesion rate; a secondary analysis investigated time to introduce USWT. Results The baseline clinical characteristics were similar between the two groups, with the exception of the mean length of stay. The length of stay was significantly longer for the USWT group (10.9 ± 3.1 vs. 9.4 ± 2.4 days, p = 0.01). The resolution of lesions was significantly higher (97.3 vs. 72.0%, p < 0.01), and new lesion rates were lower in the USWT group (16.2 vs. 29.3%), but not significant (p = 0.20). The multivariate analysis confirmed that USWT and severity of pneumonia were significant independent variables affecting lung length of stay (p <0.01; p <0.001). Conclusions USWT as adjunctive therapy for children with MRMPP significantly improved resolution of pulmonary lesions, while also being associated with…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.